why glp 1 Glucagon-like peptide in health and disease Is GLP-1 the Same as

Garcia says

For example, patients using liraglutide (Victoza) may experience more gastrointestinal side effects than those using semaglutide (Ozempic), which tends to cause fewer issues for many patients

Epigenetic silencing of mir-210 increases the proliferation of gastric epithelium during chronic helicobacter pylori infection

The injectable obesity medications Semaglutide 2.4 mg, a selective GLP-1 receptor agonist, produces robust and durable weight loss of approximately 1516% over 68 weeks ( Tirzepatide, a dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonist, delivers even greater weight loss, exceeding 20% at the highest dose in pivotal trials ( Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, represents a further step in efficacy, with 24.2% weight loss achieved within 48 weeks in phase 2 studies ( Survodutide, an oxyntomodulin analogue, achieved clinically meaningful weight loss ( Table 2